Last reviewed · How we verify
alpha-glucosidase inhibitor
Alpha-glucosidase inhibitors slow the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose spikes.
Alpha-glucosidase inhibitors slow the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose spikes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | alpha-glucosidase inhibitor |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Alpha-glucosidase inhibitor |
| Target | Alpha-glucosidase enzymes (intestinal brush border) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
These drugs competitively inhibit enzymes (alpha-glucosidases) on the intestinal brush border that break down disaccharides and oligosaccharides into monosaccharides. By delaying carbohydrate hydrolysis and absorption, they reduce the rate at which glucose enters the bloodstream after meals, thereby lowering postprandial glucose excursions in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)
- Abdominal pain
- Constipation
Key clinical trials
- GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM (PHASE4)
- Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes (PHASE3)
- Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) (NA)
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients (PHASE3)
- Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes
- A Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract) (NA)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- alpha-glucosidase inhibitor CI brief — competitive landscape report
- alpha-glucosidase inhibitor updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI